Emmanuel Deau

Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.

Y. Hérault, L. Meijer, Thu Lan Nguyen, 2021, Journal of medicinal chemistry.

Congenital heart defects in Down syndrome are caused by increased dosage of DYRK1A

A. Snijders, Rifdat Aoidi, Ok-Ryul Song, 2023, bioRxiv.

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome

A. Snijders, M. Gutierrez, Rifdat Aoidi, 2024, Science Translational Medicine.

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia

T. Mercher, R. Kotecha, Andrew P. Montgomery, 2024, Haematologica.